Skip to content. Skip to navigation
Sections
Personal tools
You are here: Home
Featured Journal
Navigation
Site Search
 
Search only the current folder (and sub-folders)
Log in


Forgot your password?
New user?
Check out our New Publishers' Select for Free Articles
Journal Search

Antiviral Research (v.74, #3)

Mutations in the RNaseH Region Observed in the HIV-1 of Antiretroviral Treatment (ART) Experienced Patients by J. Waters; W. O’Neal; K. White; E. Lansdon; M. Miller; J. Harris; K. Borroto-Esoda (pp. a28).
Inhibition of the Tax-Dependent Human T-Lymphotropic Virus Type 1 (HTLV-1) Replication in Persistently Infected Cells by the Naphthalene Derivative JTK-101 by Xin Wang; Minyi Shi; Jun-ichi Fujisawa; Yuetsu Tanaka; Shuji Izumo; Satoru Ikeda; Masanori Baba (pp. a81).
New Digital Method of Virus-Cell Interaction Description by Andriy Fedchuk; Oleksandr Fedchuk; Alla Fedchuk; Pavlo Fedchuk (pp. a53).
Involvement of New Mutational Pattern in HIV-1 gp41 in T-20 Treatment by Stefano Aquaro; Valentina Svicher; Roberta D’Arrigo; Mario Santoro; Giovanni Di Perri; Sergio Lo Caputo; Ubaldo Visco-Comandini; Pasquale Narciso; Andrea Antinori; Carlo Federico Perno (pp. a28-a29).
Fractal Microscope—Multipurpose Device For Antiviral Research by Oleksandr Fedchuk; Andriy Fedchuk; Alla Fedchuk; Pavlo Fedchuk (pp. a53-a54).
Drug Resistance to Tipranavir (TPV) or Darunavir (DRV) According to New Interpretation Algorithms in PI-naïve HIV-1 Infected Patients by M. Stuermer; B. Dauer; A. Haberl; A. Mueller; P. Gute; S. Klauke; S. Staszewski; H.W. Doerr (pp. a29).
Sublingual Delivery of SB 9000—An Anti-HBV Dinucleoside Phosphorothioate Analog by Radhakrishnan Iyer; Padma Devarajan; Sayalee Shastri; Swati Guhagarkar; Rita Mulherkar; Ganesh Joshi; Seetharamaiyer Padmanabhan; John Coughlin (pp. a54).
Design, Synthesis, Antiviral Activity and Cytotoxicity of Novel Sulphonamide Derivatives by P. Selvam; D.F. Smee; B.B. Gowen; C.W. Day; D.L. Barnard; J.D. Morrey (pp. a81).
Development of a Cell-Based Assay for Identification of Viral Entry Inhibitors Against SARS-CoV by High Throughput Screening (HTS) by Chengsheng Zhang; Yan Feng; Gillian Wong; Liping Wang; Jonathan Cechetto; Jan Blanchard; Eric Brown; James Mahony (pp. a82).
The Inhibitory Effects of Medicinal Herbs on SARS-CoV Entry In Vitro by Min Zhuang; Hong Jiang; Peng Xiao; Yasuhiro Suzuki; Toshio Hattori (pp. a82-a83).
Characterization of Influenza Virus Clinical Isolates Obtained During Clinical Study of Arbidol by Irina Leneva; Elena Burtseva; Elena Shevchenko; Alexander Shuster (pp. a55).
Discovery of a New Class of Polycyclic RSV Inhibitors by Silas Bond; Alistair Draffan; John Lambert; Chin-Yu Lim; Bo Lin; Angela Luttick; Jeff Mitchell; Craig Morton; Roland Nearn; Vanessa Sanford; Simon Tucker (pp. a30).
Initial Pharmacodynamic Evaluation of Orally Bioavailable Prodrugs of SB-9000, a Novel Anti-HBV Agent by Radhakrishnan Iyer; Seetharamaiyer Padmanabhan; John Coughlin; Guangrong Zhang; Cassandra Kirk; Brent Korba; John Morrey (pp. a54-a55).
Preclinical Development of A New Class of Orally Active Drug Candidates for the Treatment of RSV Infections by Angela Luttick; Bo Lin; Craig Morton; Simon Tucker; Silas Bond; Alistair Draffan; John Lambert; Chin-Yu Lim; Jeff Mitchell; Vanessa Sanford; Jane Ryan; Annette Kerr; Jega Iswaran; JoAnn Suzich; Mike McCarthy (pp. a55).
Potent Inhibition of Viral Entry and Replication of SARS-CoV by siRNAs Targeting the Genes Encoding the Cellular ACE2 Receptor or the Viral Nucleocapsid Protein by Xin Yan; Hua Shen; Yan Feng; Jun Wang; Shiwen Lou; Liping Wang; Gillian Wong; Zhaoxiong Yang; Hongjian Jiang; Xinqi Wu; Dan Hu; Yi Guan; Fiona Smaill; Chengsheng Zhang (pp. a30-a31).
Generation and Characterization of Fully Human Antibodies Against Orthopoxviruses by Tatynana Yun; Nina Tikunova; Ludmila Shingarova (pp. a56).
Solid-phase synthesis of the anti-HBV dinucleotide SB 9000—Microwave-assisted Functionalization of Solid Supports by Seetharamaiyer Padmanabhan; John Coughlin; Radhakrishnan Iyer (pp. a88).
Oseltamivir-Ribavirin Combination Therapy for Highly Pathogenic H5N1 Influenza Virus Infection in Mice by Natalia A. Ilyushina; Robert G. Webster; Elena A. Govorkova (pp. a31-a32).
Selection of Human Cytomegalovirus Resistant to a Second Generation Methylenecyclopropane Purine by Katherine Z. Borysko; Julie M. Breitenbach; Brian G. Gentry; Jiri Zemlicka; John C. Drach (pp. a83-a84).
The Combination of Anti-poxvirus Compounds ST-246 and TTP-018 are Synergistic In Vitro by Yali Chen; Chris Harver; Guang Yang; Dennis Hruby; Robert Andrews; Robert Jordan (pp. a84).
Susceptibility of German Porcine H3N2 Influenza A viruses Against Existing Antiviral Drugs by Katja Bauer; Christina Schrader; Jochen Suess; Peter Wutzler; Michaela Schmidtke (pp. a56-a57).
Anti-HBV Nucleotide Prodrug Analogs: Synthesis, Bioreversibility, and Cytotoxicity Studies by Seetharamaiyer Padmanabhan; John Coughlin; Guangrong Zhang; Cassandra Kirk; Radhakrishnan Iyer (pp. a89).
Intramuscular Administration of Neuraminidase Inhibitor Peramivir Promotes Survival Against Lethal H5N1 Influenza Infection in Mice by David A. Boltz; Natalia A. Ilyushina; C. Shane Arnold; Y. Sudhakar Babu; Robert G. Webster; Elena A. Govorkova (pp. a32).
Thiazolobenzimidazoles, a Novel Class of Enterovirus Inhibitors, Target the 2C Protein by Armando M. De Palma; Ward Heggermont; Erik De Clercq; Alba Chimirri; Johan Neyts (pp. a84).
Activation of GS-7340 and Other Tenofovir Phosphonoamidate Prodrugs by Human Proteases by Gabriel Birkus; Nilima Kutty; Gong-Xin He; Andrew Mulato; William Lee; Martin McDermott; Tomas Cihlar (pp. a57).
Carbohydrate-Binding Agents (CBAs) Potently Inhibit HIV Infection In Human Primary Monocytes/Macrophages and Efficiently Prevent Viral Capture and Subsequent Transmission to CD+4 T Lymphocytes by Michela Pollicita; Stefano Aquaro; Willy J. Peumans; Els J.M. Van Damme; Carlo Federico Perno; Dominique Schols; Jan Balzarini (pp. a55-a56).
Treatment of Paralysis Caused by West Nile Virus in Hamsters by John D. Morrey; Venkatraman Siddharthan; Hong Wang; Aaron L. Olsen; Ramona Skirpstunas; Jeffery O. Hall; Hua Li; Scott Koenig; Syd Johnson; Jeffrey L. Nordstrom; Nicole Marlenee; Richard A. Bowen; Michael S. Diamond (pp. a32).
Thiazolides: A New Class of Broad-Spectrum Antiviral Drugs Targeting Virus Maturation by M. Gabriella Santoro; Alessandra Ciucci; Patrizia Gianferretti; Giuseppe Belardo; Simone La Frazia; Stefania Carta; Jean-Francois Rossignol (pp. a31).
Selective Phosphorylation of Antiviral Drugs by Vaccinia Virus Thymidine Kinase by Emma Harden; Kathy Keith; Mary Johnson; Alexis McBrayer; Ming Luo; Shihong Qiu; Debasish Chattopadhyay; Xuesen Fan; Paul Torrence; Earl Kern; Mark Prichard (pp. a84-a85).
Synthesis and Structure–Activity Aspects of Some Cyclic Cidofovir Peptidomimetic Prodrugs by Larryn W. Peterson; Boris A. Kashemirov; Katarzyna M. Blazewska; Julie Breitenback; Kathy Borysko; John C. Drach; Jae Seung Kim; Paul Kijek; John M. Hilfinger; Charles E. McKenna (pp. a33).
Intracellular Localization of Herpes Simplex Virus Type 1 Thymidine Kinase in Cells Infected with Various Thymidine Kinase-Deficient Viruses by Chong-Kyo Lee; Ju Ryung Nam; Pan Kee Bae; Jee Hyun Kim; Hae Soo Kim; Myung-Jin Lee (pp. a85).
Development of ATP/Luminescence Assays For Profiling Compounds Against A Panel of Positive-Strand RNA Viruses by Edwin Gong; Tania Ivens; Christel Van den Eynde; Sabine Hallenberger; Kurt Hertogs (pp. a58).
Synthesis and Antiviral Activity of 1-( S)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl]-5-Azacytosine and its Ester Prodrugs by Marcela Krecmerova; Antonin Holy; Alois Piskala; Graciela Andrei; Robert Snoeck; Lieve Naesens; Johan Neyts; Jan Balzarini; Erik De Clercq (pp. a33).
Substrate Specificity and Molecular Modelling of Feline Herpesvirus-1 Thymidine Kinase by Islam Mohammad; Ricardo Nunez; Laurence Tiley; Hugh Field (pp. a85).
In Vivo Antiviral Activity of 1-( S)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl]-5-Azacytosine and its Cyclic Form by Graciela Andrei; Marcela Krecmerová; Antonín Holý; Lieve Naesens; Johan Neyts; Jan Balzarini; Erik De Clercq; Robert Snoeck (pp. a33-a34).
Influence of Substitutes in the Central Phenyl Ring of Capsid Function Inhibitors on Anti-coxsackievirus B3 Activity by Michaela Schmidtke; Olga Riabova; Vadim Makarov; Peter Wutzler (pp. a86).
Development and Validation of a High Throughput Screen for Inhibitors of Respiratory Syncytial Virus by Marintha Heil; Michael McDowell; Colleen Jonsson; William Severson (pp. a59).
Evidence For In Vivo Inhibition of CMV Infection by the Quinazoline Class Protein Kinase Inhibitor Gefitinib by Mark Schleiss; Michael McVoy; Xiaohong Cui; Yeon Choi; Jodi Anderson; Thomas Stamminger; Bert Klebl; Jan Eickhoff; Manfred Marschall (pp. a34-a35).
Successful Treatment in the Monkeypox and Variola Primate Models of Smallpox by the Oral Drug ST-246 by John Huggins; Arthur Goff; Mucker Eric; Nancy Twenhafel; Jennifer Chapman; Mallory Tate; Rob Jordan; Tove’ Bolken; Dennis Hruby (pp. a35).
Chemical Stability and Intracellular Metabolism of 1-( S)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl]-5-Azacytosine by Lieve Naesens; Graciela Andrei; Ivan Votruba; Marcela Krecmerová; Antonín Holý; Jan Balzarini; Erik De Clercq; Robert Snoeck (pp. a86).
shRNAs Targeting Hepatitis C: Effects of Sequence and Structural Features, and Comparison with siRNA by Brian Johnston; Alexander Vlassov; Brent Korba; Heini Ilves; Roger Kaspar; Sergei Kazakov; Kristine Farrar; Sampa Mukerjee; Attila Seyhan (pp. a59-a60).
Design and Characterization of R1626, A Prodrug of the HCV Replication Inhibitor R1479 (4′-Azidocytidine) With Enhanced Oral Bioavailability by Klaus Klumpp; David Smith; Michael Brandl; Tom Alfredson; Keshab Sarma; Mark Smith; Isabel Najera; Wen-Rong Jiang; Sophie Le Pogam; Vincent Leveque; Han Ma; Yaping Tu; Rebecca Chan; Chiao-Wen Chen; Xiaoyang Wu; Raj Birudaraj; Steven Swallow; Joseph A. Martin; Nick Cammack; Heather Berns; Scott Fettner; David Ipe; Marie Mannino; Edward O’Mara; Carla Washington; Stuart Roberts; Graham Cooksley; Greg Dore; David Shaw; David R. Blue Jr.; Friederike Zahm; George Hill (pp. a35).
Enhanced Potency and Efficacy of 29-mer shRNAs in Inhibition of Enterovirus 71 by Eng-Lee Tan; May-Chin Tan; Vincent Tak-Kwong Chow; Chit-Laa Poh (pp. a87-a88).
Synthesis and Anti-HBV Activity of 7-Deaza-Neplanocin A Analogs by Hyo-Joong Kim; Ashoke Sharon; B.E. Korba; Chung K. Chu (pp. a60).
Novel 4′-Azido-2′-Deoxy-Nucleoside Analogs are Potent Inhibitors of NS5B-Dependent HCV Replication by David Smith; Han Ma; Sophie Le Pogam; Vincent Leveque; Carl Brown; Nils Gunnar Johansson; Genadiy Kalayanov; Staffan Eriksson; Elena Usova; Christian Sund; Anna Winqist; Tatiana Maltseva; Mark Smith; Joseph Martin; Isabel Najera; Klaus Klumpp (pp. a36).
A Novel Class of Amphipathic DNA Polymers Inhibits Hepatitis C Virus Infection by Blocking Viral Entry by Takuya Matsumura; Takanobu Kato; Zonghi Hu; Jean-Marc Juteau; Andrew Vaillant; Jake Liang (pp. a60).
Characterization of the Intracellular Metabolism of β-d-2′-Deoxy-2′-Fluoro-2′-C-Methyl-Cytidine and the Inhibition of HCV Polymerase NS5B by its 5′-Triphosphate Species by Han Ma; Wen-Rong Jiang; Nicole Robledo; Vincent Leveque; Samir Ali; David Smith; Mohammad Masjedizadeh; Teresa Lara-Jaime; Nick Cammack; Klaus Klumpp; Julian Symons (pp. a36).
Pharmacodynamics of NPI-5291, an Adamantane Class Compound, for Influenza A Viruses by James McSharry; Kris Zager; Qingmei Weng; David Chernoff; George Drusano (pp. a61).
Nucleosidic Fusion Inhibitors by M. St. Vincent; S. Korkach; O. Valueva; V. Korshun; A. Ustinov; L. Schang (pp. a87).
Sub Micromolar Inhibitors of HCV Generated from Inactive Nucleosides by Application of ProTide Technology by Christopher McGuigan; Plinio Perrone; Giovanna Luoni; Mary Rose Kelleher; Felice Daverio; Annette Angell; Sinead Mulready; Costantino Congiatu; Sonal Rajyaguru; Joseph Martin; Vincent Lévêque; Sophie Le Pogam; Isabel Najera; Klaus Klumpp; David Smith (pp. a36-a37).
High Throughput Screening of a 100,000 Compound Library for Inhibitors of Influenza A Virus (H3N2) by William Severson; Michael McDowell; Lynn Rasumussen; Mindy Sosa; Subramaniam Ananthan; James Noah; Lucile White; Colleen Jonsson (pp. a62).
Substituted Imidazopyridines as Potent Inhibitors of Hepatitis C Virus Replication that Target the Viral Polymerase by Inge Vliegen; Jan Paeshuyse; Laura S. Lehman; Weidong Zhong; Sofie Roofthooft; Hélène Dutartre; Barbara Selisko; Bruno Canard; Nina Boddeker; Steven Bondy; David Oare; Erik De Clercq; William A. Lee; Gerhard Pürstinger; Johan Neyts (pp. a37).
Antiviral Activity of Reverse Transcriptase Inhibitors against Porcine Endogenous Retroviruses (PERV) by Minyi Shi; Xin Wang; Erik De Clercq; Sonshin Takao; Masanori Baba (pp. a62).
17-AAG, an Hsp90 Inhibitor, Suppress Hepatitis C Virus (HCV) Replication by Saneyuki Ujino; Kunitada Shimotohno; Hiroshi Takaku (pp. a62-a63).
The Triple Combination of Tenofovir, Emtricitabine and Efavirenz Shows Synergistic Anti-HIV-1 Activity In Vitro by F. Myrick; J. Feng; E. Svarovskaia; M. Miller; K. Borroto-Esoda (pp. a61).
GL59728: A Potent Allosteric Inhibitor of the HCV NS5b RNA Dependent RNA Polymerase with Excellent Pharmacokinetic Properties by Christopher Roberts; Janos Botyanszki; Dong-fang Shi; Joshua Gralapp; Samantha Koo-McCoy; John Zhang; Kevin Fung; Mohan Sivaraja; Jeffrey Pouliot; Ting Wang; Kevin Dunlop; Wenbao Li; Lillian Lou; Uli Schmitz; Peter Young; Ron Griffith (pp. a37).
Potent HCV NS5B Polymerase Inhibitors Derived From 5-Hydroxy-3(2H)-Pyridazinones: Part 1 by Y. Zhou; L.-S. Li; S. Webber; P. Dragovich; D. Murphy; C. Tran; F. Ruebsam; A. Shah; M. Tsan; R. Showalter; J. Brooks; E. Okamoto; T. Nolan; D.A. Norris; L. Kirkovsky (pp. a38).
Development of Anti-Infective Topical Microbicides by Karen Watson; Lu Yang; Robert Buckheit Jr. (pp. a63).
The Cyclophilin Inhibitor Debio-025 is a Potent Inhibitor of Hepatitis C Virus Replication in vitro With a Unique Resistance Profile by Lotte Coelmont; Jan Paeshuyse; Suzanne Kaptein; Inge Vliegen; Artur Kaul; Erik De Clercq; Brigitte Rosenwirth; Pietro Scalfaro; Raf Crabbé; Ralf Bartenschlager; Jean-Maurice Dumont; Johan Neyts (pp. a39).
Development of Anti-Infective Topical Microbicides by Karen Watson; Lu Yang; Robert Buckheit Jr. (pp. a63).
The Imidazopyrrolopyridine Analogue AG110 is a Novel, Highly Selective Inhibitor of Pestivirus Replication and Targets the viral RNA-dependent RNA Polymerase by Jan Paeshuyse; Jean-Michel Chezal; Matheus Froeyen; Pieter Leyssen; Hélène Dutartre; Robert Vrancken; Bruno Canard; Carine Letellier; Tong Li; Harald Mittendorfer; Frank Koenen; Pierre Kerkhofs; Erik De Clercq; Piet Herdewijn; Gerhard Puerstinger; Alain Gueiffier; Olivier Chavignon; Jean-Claude Teulade; Johan Neyts (pp. a39).
Development of Anti-Infective Topical Microbicides by Karen Watson; Tracy Hartman; Lu Yang; Robert Buckheit Jr. (pp. a64).
Nitazoxanide is an Effective Antiviral Agent Against Both HBV and HCV replication in vitro by Brent Korba; Muller Abigail; Ayers Marc; Jean-François Rossignol (pp. a40).
Development of Hepatitis C Virus (HCV) Chimeric Replicons for Identifying Broad Spectrum NS3 Protease Inhibitors by Joseph Binder; Selwyna Tetangco; Megan Wick; Karen Maegley; Laura Lingardo; Amy Patick; George Smith (pp. a38).
Peptidomimetic Dimerization Inhibitors of HIV-1 Protease: Further Insights into Structural Variations and Mechanism of Action by Ludovic Bannwarth; Thierry Rose; Silvia Frutos; Ernest Giralt; Regis Vanderesse; Brigitte Jamart-Grégoire; Anamaria Vidu; Sandrine Ongeri; Sames Sicsic; Christophe Pannecouque; Erik De Clercq; Michèle Reboud-Ravaux (pp. a64).
Efficacy of Cationic Lipid-DNA Complexes (CLDC) on Hepatitis B Virus in Transgenic Mice by John D. Morrey; Neil E. Motter; Brandon Taro; Fairman Jeffery (pp. a40).
A High Throughput HIV-1 Full Replication Assay that Includes HIV-1 Vif as an Antiviral Target by Joan Cao; Jason Isaacson; Amy Patick; Wade Blair (pp. a64-a65).
DC-SIGN is Not Required for HIV-1 Transmission to CD4+ T Lymphocytes by Imma Clotet-Codina; Berta Bosch; Ruth Peña; Bonaventura Clotet; Margarita Bofill; José A. Esté (pp. a65).
Structural Basis for the Expanded Substrate Specificity of Vaccinia Virus Thymidine Kinase: Insight from the Crystal Structure by Mark Prichard; Kathy Keith; Mary Johnson; Norbert Schormann; Alexandra Samal; Debasish Chattopadhyay; Earl Kern (pp. a41).
The Virtues of Unique Ribonucleotide Reductase Inhibitors Didox and Trimidox for Retrovirus Therapy by Howard Elford; Ron Lee; Jadwiga Turchan; Vincent Gallicchio; Michael Ussery; John Hiscott; Avindra Nath (pp. a65-a66).
Inhibition of an Innate Antiviral Response by Human Cytomegalovirus UL97 Kinase is Antagonized by Maribavir by Mark Prichard; Shannon Daily; Amie Perry; Caroll Hartline; Earl Kern (pp. a41-a42).
Human Immunodeficiency Virus Type 1 Does Not Escape from Novel Single-Stranded Dnazyme Expression-Mediated Inhibition by Masaak Hyafune; Yuka Mouri; Naoko Miyano-Kurosaki; Kahoko Hashimoto; Hiroshi Takaku (pp. a66).
Editorial Board (pp. ii).
Vaccination as an Antiviral Strategy for Control of Cytomegalovirus (CMV) Disease: A Vectored Vaccine Approach Targeting the UL83 (pp65) Homolog Protects Against Congenital CMV Disease in the Guinea Pig Model by Mark Schleiss; Juan Lacayo; Yasmine Belkaid; Alistair McGregor; Greg Stroup; Jon Rayner; Kim Alterson; Jeff Chulay; Jonathan Smith (pp. a42).
Characterization of a New Class of Polycyclic RSV Inhibitors by Angela Luttick; Bo Lin; Craig Morton; Simon Tucker; Silas Bond; Alistair Draffan; John Lambert; Chin-Yu Lim; Jeff Mitchell; Vanessa Sanford; Mike McCarthy; JoAnn Suzich; Nita Patel; Bettina Richter (pp. a66).
HIV Coreceptor Switch Induced by Antagonism to CCR5 by Gemma Moncunill; Mercedes Armand-Ugón; Bonaventura Clotet; José A. Esté (pp. a66-a67).
JuvImmune is a Novel Vaccine Adjuvant that Enhances Protection of Mice from Lethal HSV-2 Infection Following Immunization by Jane Strasser; Rhonda Cardin; Claudia Chalk; James Ireland; Jeff Fairman; David Bernstein (pp. a42).
Comparative Activity of Anti-Enteroviral Agents Against Poliovirus Replication In Vitro by Armando M. De Palma; Gerhard Pürstinger; Amy Patick; Koen Andries; Erik De Clercq; Bart Rombaut; Johan Neyts (pp. a43).
Induction of IL-6 and IL-8 by siRNAs Targeting HIV Correceptor CCR5 by Eduardo Pauls; Jordi Senserrich; Margarita Bofill; Bonaventura Clotet; Jose Esté (pp. a67).
Carbohydrate-Binding Agents (CBAs) Selectively Target the Glycoproteins of the HCV and HIV Envelope to Prevent Viral Entry by J. Balzarini; C. Bertaux; D. Daelemans; M. Meertens; E.G. Cornier; J.F. Reinus; W.J. Peumans; E.J.M. Van Damme; Y. Igarashi; T. Oki; D. Schols; T. Dragic (pp. a43).
Identification and Characterization of a Novel, Potent HCV Helicase Inhibitor by Junzhong Peng; Chunsheng Huang; Michael G. Murray; Zhuhui Huang (pp. a67).
In Vitro and In Vivo Activity of T-705 Against Arenavirus and Bunyavirus Infections by Kie-Hoon Jung; Min-Hui Wong; Yousuke Furuta; Andrew Sanders; Michelle Mendenhall; Kevin Bailey; Robert Sidwell; Brian Gowen (pp. a44).
Design, Synthesis and Anti-HIV Activity of Some Novel Isatin Derivatives by Periyasamy Selvam; Narayanan Murugesh; Markandavel Chandramohan; Zeger Debyser; Myriam Witvrouw; Yves Engelborghs (pp. a68).
QSAR Studies On [(Biphenyloxy)propyl]isoxazole Derivatives With Anti-rhinovirus 2 Activity by E. Muratov; V. Kuz’min; A. Artemenko; I. Volineckaya; V. Makarov; O. Riabova; P. Wutzler; M. Schmidtke (pp. a44).
Design and Cellular Kinetics of Dansyl-labeled CADA Derivatives with Specific Anti-HIV and CD4 Receptor Down-modulating Properties by Kurt Vermeire; Andrea Lisco; Jean-Charles Grivel; Paul Blank; Vincent Schram; Noah Duffy; Emily Scarbrough; Kaka Dey; Thomas Bell; Leonid Margolis; Dominique Schols (pp. a68-a69).
Notes to Authors (pp. co3).
Intranasal Protollin Formulated Recombinant SARS-CoV S Protein Elicits Respiratory and Serum Neutralizing Antibodies by Dale Barnard; Mary Hu; Taff Jones; Richard Kenney; David Burt; George Lowell (pp. a45).
An Animal Model of HCMV Infection in SCID Mice by Fernando Bravo; Rhonda Cardin; David Bernstein (pp. a69).
Bile Acid Conjugates Improve the Oral Bioavailability of the Neurominidase Inhibitor Zanamivir by Phillip Kish; Jae Seung Kim; Blake Roessler; Shelby Campbell; John Hilfinger (pp. a45-a46).
HIV-1 Resistance to the Anti-HIV Activity of a siRNA Targeting Rev by Jordi Senserrich; Eduardo Pauls; Bonaventura Clotet; Jose A. Esté (pp. a68).
Lymphocytic Necrosis in Hamsters Inoculated with Western Equine Encephalitis Virus by Aaron Olsen; John Morrey; Justin Julander; Jeffery Hall; Ramona Skirpstunas; Robert Sidwell (pp. a46).
Antiviral Activity of (−)-Carbocyclic Cytosine [(−)-Carbodine] Against Venezuelan Equine Encephalitis Virus (VEEV) in a Mouse Model by Justin Julander; Chung Chu; Jagadeeshwar Rao; Kristiina Shafer; John Morrey (pp. a44-a45).
Efficacy of Oral CMX-001 Therapy Against Human Herpes Virus-6 Infections in SCID-hu Mice by Debra Quenelle; Mark Prichard; Shannon Daily; Deborah Collins; Terri Rice; George Painter; Alice Robertson; Earl Kern (pp. a70).
Contents of Volume (pp. a98-a99).
Efficacy of Delayed Therapy Using Combinations of ST-246 with CMX-001 Against Systemic Cowpox Virus Infections in Mice by Debra Quenelle; Mark Prichard; Kathy Keith; Deborah Collins; Robert Jordan; Dennis Hruby; George Painter; Alice Robertson; Earl Kern (pp. a70).
Design and Synthesis of Novel Anti-HCMV Agents: Modifications to the Bicyclic Pyrimidine Base by Rina Adak; Christopher McGuigan; Robert Snoeck; Graciella Andrei; Eric De Clercq; Jan Balzarini (pp. a71).
Anti-Influenza A Synergistic Combination Effect of Rimantadine and Oseltamivir in Mice by Lora Simeonova; Angel S. Galabov; Galina Gegova (pp. a46-a47).
Phosphorodiamidate Morpholino Oligomer—Mediated Inhibition of Influenza A Virus in Mice by Thomas Voss; Kelly Warfield; Rebecca Brocato; Joseph Barbercheck; Bryan Kaplin; David Stein; Sina Bavari; Patrick Iversen (pp. a47).
HINT as Putative Phosphoramidase Responsible of ProTides Activation: Molecular Modelling Studies by Costantino Congiatu; Christopher McGuigan; Andrea Brancale (pp. a71).
Design, Synthesis, and Biological Evaluation of Novel Anti-VZV Agents by Marco Derudas; Christopher McGuigan; Robert Snoeck; Graciella Andrei; Erik De Clercq; Jan Balzarini (pp. a72).
Synthesis and Properties of Chiral Open-Ring Acyclic Nucleoside Bisphosphonates by Petra Doláková; Martin Dračínský; Antonín Holý (pp. a72).
Synthesis, Anti-HIV and CD4 Down-Modulation Activities of Novel CADA Compounds by Sreenivasa Anugu; Thomas Bell; Noah Duffy; Kurt Vermeire; Dominique Schols (pp. a48).
Synthesis and Antiviral Evaluation of Iso-methyl-alkoxyalkyl (S)-HPMPA Esters by James R. Beadle; Karl Y. Hostetler; R. Mark Buller; Jill Schriewer; Kathy A. Aldern; Mark N. Prichard; Kathy Keith; Earl R. Kern (pp. a48).
Properties of Aminoacid Esters Linked to Cyclo Sal-Pronucleotides by Henning Jessen; Jan Balzarini; Chris Meier (pp. a73).
Raft-tropic Antivirals: 1 by Y. Egorov; A. Serbin; O. Alikhanova; M. Burshtein; S. Lupandin; A. Bukrinskaya (pp. a49).
Discovery of Cage Antiviral Agents by Yuri Klimochkin; Eugene Boreko; Andrey Shiryaev; Igor Moiseev; Eugene Golovin; Marina Leonova (pp. a73).
Future Conferences (pp. a97).
7-Deaza Neplanocin Analogs Inhibit Hepatitis C Virus (HCV) in Vitro by H.J. Kim; J.N. Wang; Z.H. Huang; M.G. Murray; R.F. Schinazi; C.K. Chu (pp. a49).
Pyrimidine Nucleosides Containing 5-Substituent: Synthesis and Antiviral Activity by Stanislav V. Korkach; Olga A. Valueva; Veronika V. Doubniakova; Vladimir A. Korshun; Alexey V. Ustinov (pp. a73).
QSAR Analysis of Anti-Coxsackievirus B3 Nancy Activity of 2-Amino-3-Nitropyrazole[1,5-α]Pyrimidines by Means of Simplex Approach by V. Kuz’min; E. Muratov; A. Artemenko; I. Volineckaya; V. Makarov; O. Riabova; P. Wutzler; M. Schmidtke (pp. a49-a50).
New Ribonucleosides with Surrogate Bases: Synthesis, Enzymology, Molecular Docking Studies and Antiviral Activity by Vasu Nair; Xiaohui Ma; Fan Zhang; Malik Nishonov; Qingning Shu; Robert Sidwell; Earl Kern (pp. a74).
Brivudin (ZostexR) in the Treatment of Herpes Zoster in Immunosuppressed Patients by Astrid Meerbach; Peter Wutzler; Bernd Gruhn (pp. a75).
Novel Synthetic Approaches to Cidofovir and Foscarnet Prodrugs by Larryn W. Peterson; Boris A. Kashemirov; Kanokkarn Saejueng; Julie Breitenbach; Kathy Borysko; John C. Drach; Jae Seung Kim; Paul Kijek; Stefanie Mitchell; John M. Hilfinger; Charles E. McKenna (pp. a74).
Novel Diketo Phosphonic Acids Constructed on Nucleobase Scaffolds: Design, Synthesis, Molecular Modeling and Anti-HIV Activity by Vasu Nair; Guochen Chi; Iwona Dams; Byung Seo; Vinod Uchil; Arthur Cox (pp. a50).
Enhanced Antiviral Activity of Hexadecyloxypropyl-PME- N6-Cyclopropyl-diaminopurine Against Herpesviruses, Hepatitis B Virus and Vaccinia Virus, In Vitro by Graciela Andrei; Robert Snoeck; Johan Neyts; Erik De Clercq; Nadejda Valiaeva; James Beadle; Karl Hostetler (pp. a76).
Molecular Design of Active Antiherpetic Compounds Using Hierarchic QSAR Technology by A. Artemenko; V. Kuz’min; E. Muratov; A. Fedchuk; V. Lozitsky; T. Gridina; R. Lozytska; S. Basok; D. Chikhichin (pp. a76).
Anti-orthopoxviral Activity of the 2-Cycloalkylimino-5-(4-Nitrophenyl)-1,3,4-Thiadiazines by Evgeny Belanov; Larisa Sidorova; Vladimir Rusinov; Nikolay Bormotov; Sergey Balakhnin; Olga Serova; Valerii Charushin; Oleg Chupakhin (pp. a77).
Proteflasid as Inhibitor of EBV-infection by N. Nesterova; S. Zagorodnya; G. Baranova; A. Golovan; V. Atamaniuk; A. Novik (pp. a75).
Discovery of Novel Small Molecule Inhibitors of Dengue Virus Replication by Chelsea Byrd; Eric Stavale; Andrews Wieczorek; Thaun Tran; Dennis Hruby; Robert Jordan (pp. a77).
Antiviral Activities of New Cidofovir Analogs Against Camelpox Virus, Used as a Model of Variola Virus, in Human Skin Equivalent Cultures by Sophie Duraffour; Robert Snoeck; Joost Van Den Oord; Marcela Krecmerová; Antonín Holý; Jean-Marc Crance; Daniel Garin; Erik De Clercq; Graciela Andrei (pp. a78).
Cytopathic Maporal Hantavirus Infection of Vero E6 Cells by Brian Gowen; Kie-Hoon Jung; Michelle Mendenhall; Irina Gavrilovskaya; Siddharthan Venkatraman; Erich Mackow; Robert Sidwell (pp. a78).
Comparison of Anti-Proliferative Activity of Selected Antiviral Agents in Various Assay Systems by Caroll Hartline; Harden Emma; Earl Kern; Prichard Mark (pp. a78-a79).
Synthesis and Structure Activity Relationships among Non-nucleoside Analogs of Toyocamycin Active against Herpesviruses by Jack M. Hinkley; Katherine Z. Borysko; Julie M. Breitenbach; Keenan Bora; Shigetada Kosai; John C. Drach; Leroy B. Townsend (pp. a79).
Design, Synthesis, Anti-HIV and Cytotoxicity of Novel Heterocyclic Compounds by Periyasamy Selvam; Narayanan Murugesh; Markandavel Chandramohan; Erik De Clercq; Christophe Pannecouque (pp. a51).
Combinations of CMX-001 and ST-246 Synergistically Inhibit Orthopoxvirus Replication In Vitro by Kathy Keith; Earl Kern; Shalisa Sanders; Robin Conley; Robert Jordan; Dennis Hruby; George Painter; Mark Prichard (pp. a79-a80).
Poly-Cooperation of Ionic and Non-Ionic Antiviral Vectors by A. Serbin; Y. Egorov; O. Alikhanova (pp. a51).
Inhibition of Cellular Entry and Spread of Lymphocytic Choriomeningitis Virus by Amphipathic DNA Polymers by Andrew Lee; Jillian Rojek; Anette Gundersen; Jean-Marc Juteau; Michael Oldstone; Andrew Vaillant; Stefan Kunz (pp. a80).
Potent HCV NS5B Polymerase Inhibitors Derived From 5-Hydroxy-3(2H)-Pyridazinones: Part 2 by Y. Zhou; L.-S. Li; S. Webber; B. Ayida; T. Bertolini; Z. Sun; J. Zhao; N. Stankovic; R. Patel; B. Li; L. LeBrun; R. Kamran; M. Sergeeva; D. Bartkowski; J. Khandurina (pp. a51-a52).
Identification of a Novel Small Molecule Inhibitor that Targets HIV-1 Envelope Maturation by Judith Jimenez; Joan Cao; Lynn Jackson; Qinghai Peng; Hua Wu; Jason Isaacson; Scott Butler; Amy K. Patick; Wade S. Blair (pp. a27).
Benzimidazole with Broad Spectrum of Antiviral Action by Regina Lozytska; Dmitry Chikhichin; Victror Lozitsky; Alla Fedchuk; Victor Kuz’min; Anatoly Artemenko; Larisa Shitikova; Lubov’ Mudrik; Tatjana Gridina; Eugene Muratov (pp. a80).
Synthesis of Novel Types of Anti-Coxsackie Virus Compounds by Michal Šála; Hubert Hřebabecký; Martin Dračínský; Armando De Palma; Johan Neyts; Antonín Holý (pp. a52).
Metabolism and Pharmacokinetic Studies of SB-9000—A Novel Anti-HBV agent by John Coughlin; Seetharamaiyer Padmanabhan; Radhakrishnan Iyer (pp. a52).
GS-8374, a Novel Phosphonate HIV Protease Inhibitor with Potent In Vitro Antiretroviral Activity, Low Metabolic Toxicity, and Favorable Resistance Profile by Christian Callebaut; Kirsten Stray; Luong Tsai; Lianhong Xu; Gong-Xin He; Andrew Mulato; Tina Priskich; Neil Parkin; William Lee; Tomas Cihlar (pp. a27).
The CXCR4 Antagonist POL3026 is a Potent Inhibitor of Human Immunodeficiency Virus by Gemma Moncunill; Imma Clotet-Codina; Anuska LLano; Mercedes Armand-Ugón; Bonaventura Clotet; Jan Willem Vrijbloed; José A. Esté (pp. a28).
A Rapid DNA Hybridization Assay for the Evaluation of Antiviral Compounds Against Epstein-Barr Virus by Mark Prichard; Shannon Daily; Geraldine Jefferson; Amie Perry; Earl Kern (pp. a81).
Neutralizing Human Antibodies From Immune Phage Display Antibody Library Recognize p35 Orthopoxvirus Protein by Viktoriya Dubrovskaya; Belanov Evgeniy; Bormotov Nikolay; Tikunova Nina (pp. a53).
Featured Book
Web Search
Powered by Plone CMS, the Open Source Content Management System

This site conforms to the following standards: